Edwards Lifesciences Corporation $EW Stake Increased by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans lifted its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 24.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 50,857 shares of the medical research company’s stock after buying an additional 10,045 shares during the period. Thrivent Financial for Lutherans’ holdings in Edwards Lifesciences were worth $3,978,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of EW. MASTERINVEST Kapitalanlage GmbH purchased a new stake in Edwards Lifesciences in the 2nd quarter worth about $1,742,000. Stance Capital LLC acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at about $760,000. Cim Investment Management Inc. lifted its position in shares of Edwards Lifesciences by 99.7% in the second quarter. Cim Investment Management Inc. now owns 10,123 shares of the medical research company’s stock worth $771,000 after purchasing an additional 5,053 shares in the last quarter. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Edwards Lifesciences during the second quarter worth approximately $319,000. Finally, Marex Group plc acquired a new stake in shares of Edwards Lifesciences during the second quarter worth approximately $474,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,700 shares of the firm’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total value of $650,419.00. Following the transaction, the chief financial officer directly owned 39,898 shares in the company, valued at approximately $3,370,184.06. This trade represents a 16.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 11,386 shares of the business’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $83.76, for a total transaction of $953,691.36. Following the transaction, the vice president directly owned 38,970 shares of the company’s stock, valued at approximately $3,264,127.20. This represents a 22.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 45,465 shares of company stock worth $3,804,610. 1.29% of the stock is owned by insiders.

Wall Street Analyst Weigh In

EW has been the topic of several research reports. Oppenheimer lowered shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 8th. Barclays restated an “overweight” rating and set a $103.00 price target (up from $99.00) on shares of Edwards Lifesciences in a report on Monday, December 8th. UBS Group set a $92.00 price objective on Edwards Lifesciences in a report on Friday, December 5th. National Bankshares set a $92.00 price objective on Edwards Lifesciences in a research report on Friday, October 31st. Finally, Wall Street Zen downgraded Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $93.95.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $85.66 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.00 and a quick ratio of 3.29. The stock has a market capitalization of $49.71 billion, a P/E ratio of 36.92, a P/E/G ratio of 3.85 and a beta of 0.97. The business has a 50-day moving average of $82.53 and a two-hundred day moving average of $79.28. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.89.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The firm’s revenue was up 14.7% compared to the same quarter last year. During the same period last year, the business earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, equities research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.